Emergent BioSolutions

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EBS and other ETFs, options, and stocks.

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. 

CEO
Joseph C. Papa
CEOJoseph C. Papa
Employees
900
Employees900
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1998
Founded1998
Employees
900
Employees900

EBS Key Statistics

Market cap
533.82M
Market cap533.82M
Price-Earnings ratio
7.94
Price-Earnings ratio7.94
Dividend yield
Dividend yield
Average volume
2.14M
Average volume2.14M
High today
$10.30
High today$10.30
Low today
$9.72
Low today$9.72
Open price
$10.00
Open price$10.00
Volume
1.08M
Volume1.08M
52 Week high
$13.41
52 Week high$13.41
52 Week low
$4.02
52 Week low$4.02

Stock Snapshot

Emergent BioSolutions(EBS) stock is priced at $10.24, giving the company a market capitalization of 533.82M. It carries a P/E multiple of 7.94.

During the trading session on 2025-11-07, Emergent BioSolutions(EBS) shares reached a daily high of $10.30 and a low of $9.72. At a current price of $10.24, the stock is +5.4% higher than the low and still -0.6% under the high.

Trading volume for Emergent BioSolutions(EBS) stock has reached 1.08M, versus its average volume of 2.14M.

Over the past 52 weeks, Emergent BioSolutions(EBS) stock has traded between a high of $13.41 and a low of $4.02.

Over the past 52 weeks, Emergent BioSolutions(EBS) stock has traded between a high of $13.41 and a low of $4.02.

EBS News

Nasdaq 15h
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interes...

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions
Simply Wall St 3d
Emergent BioSolutions Is Up 6.5% After Upgraded 2025 Outlook and Strong Q3 Results Has the Bull Case Changed?

Emergent BioSolutions recently reported third-quarter 2025 results, with revenue of US$231.1 million and net income of US$51.2 million, and raised its full-year...

Emergent BioSolutions Is Up 6.5% After Upgraded 2025 Outlook and Strong Q3 Results Has the Bull Case Changed?
Simply Wall St 5d
Emergent BioSolutions: Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results

Emergent BioSolutions (EBS) captured investors' attention after reporting third-quarter results that topped revenue and profitability expectations. Management r...

Emergent BioSolutions: Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results

People also own

Based on the portfolios of people who own EBS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.